Selected article for: "epitope specificity and protective immunity"

Author: Kim, Sung-Kwon; Cornberg, Markus; Wang, Xiaoting Z.; Chen, Hong D.; Selin, Liisa K.; Welsh, Raymond M.
Title: Private specificities of CD8 T cell responses control patterns of heterologous immunity
  • Document date: 2005_2_21
  • ID: 55gi6gyx_40
    Snippet: The significance of this work is in the understanding of the basic concepts of heterologous immunity. The replication of VV is reduced in LCMV-immune mice in comparison to naive mice, and T cell-dependent immunopathology is more dramatic. Adoptive transfer studies have shown that both the protective immunity and the immunopathology are dependent on T cells and on IFN-␥ production (1). It is noteworthy that IFN-␥ can be detected in vivo in dif.....
    Document: The significance of this work is in the understanding of the basic concepts of heterologous immunity. The replication of VV is reduced in LCMV-immune mice in comparison to naive mice, and T cell-dependent immunopathology is more dramatic. Adoptive transfer studies have shown that both the protective immunity and the immunopathology are dependent on T cells and on IFN-␥ production (1). It is noteworthy that IFN-␥ can be detected in vivo in different proportions of T cells of each tested LCMV epitope specificity (NP396, GP33, GP34, and NP205) by 3 d after infection, when viral titers are being controlled (3). It is not clear whether this IFN-␥ production is a consequence of T cell cross-reactivity or a nonspecific cytokine effect (28, 29) . As the infection progresses, T cells of distinct LCMV-epitope specificities expand. Given the pervasive nature of T cell cross-reactivity and the fact that it takes a stronger TCR signal to stimulate proliferation than IFN-␥ production (30) , all of these events could be determined by cross-reactivity, but this is in need of further study.

    Search related documents:
    Co phrase search for related documents
    • cell cross reactivity and cross reactivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell cross reactivity and cross reactivity determine: 1
    • cell cross reactivity and heterologous immunity: 1, 2, 3, 4, 5, 6, 7
    • cell cross reactivity and immunopathology protective immunity: 1, 2, 3
    • cell cross reactivity and LCMV epitope: 1, 2
    • cell dependent immunopathology and cross reactivity: 1
    • cell dependent immunopathology and heterologous immunity: 1
    • cross reactivity and heterologous immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • cross reactivity and immunopathology protective immunity: 1, 2, 3
    • cross reactivity and infection progress: 1
    • cross reactivity and LCMV epitope: 1, 2, 3
    • cross reactivity determine and LCMV epitope: 1
    • heterologous immunity and immunopathology protective immunity: 1, 2, 3, 4, 5
    • heterologous immunity and LCMV epitope: 1, 2, 3, 4
    • immunopathology protective immunity and LCMV epitope: 1, 2
    • immunopathology protective immunity and LCMV epitope specificity: 1